Scrip takes a look at the landscape of the South Korean gene and cell therapy sector, which is under the spotlight with the implementation of a new cutting-edge biologics law.

Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.

Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.